ApprovalTrail

Approval · Notice of Compliance 26743 · 2021

DIFFERIN: Notice of Compliance 26743

Issued September 28, 2021

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
26743
Date
September 28, 2021
Company
Galderma Canada Inc.Toronto, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other

Products in this notice

BrandDINStatus today
DIFFERINNot yet assigned—
DIFFERIN XPNot yet assigned—

Medicinal ingredients